Canadian healthcare capacity gaps for disease-modifying treatment in Huntington's disease: a survey of current practice and modelling of future needs.
Angèle BénardSylvain ChouinardBlair R LeavittNathalie BuddJennifer W WuKerrie SchofferPublished in: BMJ open (2022)
In Canada, there is little to no capacity to support the administration of an IT DMT for HD. Current inequitable and inadequate resourcing will require solutions that consider regional gaps and patient needs.